Master your fundamental research. Join 78,694 investors who trust our platform and content.
Save 54+ hours of fundamental research with free access to Stock Card.
We only ask your name and email address.
The Coronavirus pandemic engulfed the whole world at the beginning of 2020, bringing all economies to a standstill. Offices and stores closed down to prevent the spread of the virus. Developing, producing, and distributing a cure and vaccine to immunize the world population became a race many pharmaceutical companies have embarked on. Consequently, media, investors, and traders have been speculating, discussing, and pouring money into those pharmaceutical companies. The hope for a vaccine has fueled unprecedented market volatility we have rarely seen in the recent market history. After all, there is a race going on, the race to COVID-19 vaccine.
The launch of "COVID-19 Vaccine Race" collection
In May 2020, the United States government introduced a framework for 'Operation Warp Speed,' a national program to accelerate the development, production, and distribution of COVID-19 vaccines. The program aims to have the vaccines ready by January 2021. More than 100 biotech companies began investing in the development of vaccines for the COVID-19 virus in the first quarter of 2020. According to the Federal Drug Administration, as of June 2020, there have been approvals to more than 25 companies to fast track the development and testing of their vaccines. And, another 141 companies are still in the development phase.
Our research methodology
As always, the Stock Card team took on researching the most viable investment opportunities that our users and community must add to their watchlist, if they plan to participate in the race to the vaccine. We investigated different activities that support the development, production, and distribution of a vaccine and added a list of companies involved in the process to our collections and themes. This list enables you to discover promising companies to invest in easily should you choose to participate in the race to the vaccine.
To create the "COVID-19 Vaccine Race" collection, a lot of research went into understanding the whole process involved in the end-to-end development of the vaccine, and the pre- and post-vaccine steps required in the process. We identified all the industries and markets which play crucial roles in making the vaccine a success. For example, one of the primary core markets is the vaccine components and raw materials. Our research found a high demand for vaccine adjuvants, which are essential in any vaccine. Few other markets that are discussed less frequently but are as important as the vaccine development are the companies involved in the vaccine production, including glass vials, cold chain logistics, and syringes, and needles. Therefore, the race to a vaccine isn't only about Vaccine development and encompasses an entire ecosystem of companies working together to take the global population to immunity destination.
Here's a list of the primary markets vital to the vaccine development and distribution:
In the race to the COVID-19 vaccine, the competition between companies is fierce as all companies strive to win. We put together a list of 60 companies, accelerating their development to win the race. Some of these companies may be very small but watchlist-worthy. Some are large and stable, with several products already in the market. Start your research by visiting Stock Card's COVID-19 Vaccine Race collection. You can always add additional filters to narrow down the list to your portfolio's most suitable stocks.